 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innoviva, Inc. (Nasdaq: INVA) (Innoviva), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical...

Innoviva Completes Acquisition of La Jolla Pharmaceutical

StockNews.com upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC  Get Rating) from a hold rating to a buy rating in a report released on Wednesday. Separately, TheStreet raised La Jolla Pharmaceutical from a d+ rating to a c- rating in a report on Friday, July 29th. La Jolla ...

La Jolla Pharmaceutical (NASDAQ:LJPC) Upgraded at StockNews.com

StockNews.com upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC Get Rating) from a hold rating to a buy rating in a report issued on Wednesday. Separately, TheStreet raised La Jolla Pharmaceutical from a d+ rating to a c- rating in a report on Friday, July 29th. La Jolla Pharmaceutical Price ...

La Jolla Pharmaceutical (NASDAQ:LJPC  Get Rating) and Acorda Therapeutics (NASDAQ:ACOR  Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional...

La Jolla Pharmaceutical (NASDAQ:LJPC) & Acorda Therapeutics (NASDAQ:ACOR) Head to Head Comparison

SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, Aug. 3, 2022 NEW YORK, Aug. 3, 2022 /PRNewswire/ -- If you...

SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, LJPC, SMED SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, LJPC, SMED PR Newswire NEW YORK, Aug. 1, 2022 NEW YORK, Aug. 1, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is...

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, LJPC, SMED

This is a Bearish indicator signaling LJPC's price could decline from here. Traders may explore shorting the stock or put options...

La Jolla Pharmaceutical (LJPC, $6.21) Moving Average Convergence Divergence (MACD) Histogram turned negative on July 29, 2022

SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, July 28, 2022 NEW YORK, July 28, 2022 /PRNewswire/ -- If...

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of La Jolla Pharmaceutical Company (NASDAQ: LJPC) to Innoviva, Inc. for $6.23 per share in cash is fair to La Jolla shareholders. Halper Sadeh encourages La Jolla shareholders to click here to learn more about their...

LJPC Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of La Jolla Pharmaceutical Company Is Fair to Shareholders

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ZEN, LJPC, VIVO, PCSB INVESTIGATION ALERT: Halper Sadeh LLP Investigates ZEN, LJPC, VIVO, PCSB PR Newswire NEW YORK, July 27, 2022 NEW YORK, July 27, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following...

INVESTIGATION ALERT: Halper Sadeh LLP Investigates ZEN, LJPC, VIVO, PCSB

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

Watchers	5,857
52-Wk Low	$3.07
52-Wk High	$6.24

Market Cap	$158.96M
Volume (M)	267,682.00
52-Wk High	$6.24
52-Wk Low	$3.07

LJPC La Jolla Pharmaceutical Co.

About

Feed

News

Fundamentals